Evidence map›Paper›PMID 30443257›Full record

ArticleFrontiers in immunology2018

Manipulation of

Rosângela Salerno-Gonçalves, James E Galen, Myron M Levine, Alessio Fasano, Marcelo B Sztein

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04543877 (WHNRC), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04543877 early_phase1completednot on this mapstarted 2022, after this paper: background citation

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

TypeinterventionalSponsorUSDA, Western Human Nutrition Research CenterRan2022 to 2025Enrolled60ConditionsInflammation, Vaccine, Intestinal Permeability, Typhoid FeverArmsInulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Type 1 interferon-dependent repression of NLRC4 and iPLA2 licenses down-regulation ofProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rosângela Salerno-GonçalvesCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
James E GalenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Myron M LevineCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Alessio FasanoMucosal Immunology and Biology Research Center, Massachusetts General Hospital for Children, Boston, MA, United States.
Marcelo B SzteinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
University of Maryland, Baltimore · USMassachusetts General Hospital · US

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GREENWALD, BRUCE D · 2009 to 2018
$27.8M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
Zot, Zonulin, and Pathophysiology of Intestinal Tight JunctionsR01DK048373 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI FASANO, ALESSIO · 1996 to 2015
$4.4M
NIAID NIH HHS R01 AI036525NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI109776NIDDK NIH HHS R01 DK048373
6 · The paper itself

Abstract

Although immunity induced by typhoid fever is moderated and short-lived, typhoid vaccination with the attenuated Ty21a oral vaccine generates long-lasting protection rates reaching up to 92%. Thus, there are important differences on how wild-type

Indexed as

Antibodies, BacterialCells, CulturedCytokinesGene Expression Regulation, BacterialHumansImmunity, InnateInflammation MediatorsIntestinal MucosaOrgan Culture TechniquesPolysaccharides, BacterialSalmonella typhiTight JunctionsTyphoid FeverTyphoid-Paratyphoid VaccinesVaccinationVaccines, AttenuatedAntibodies, BacterialCytokinesInflammation MediatorsPolysaccharides, BacterialTy21a typhoid vaccineTyphoid-Paratyphoid VaccinesVaccines, Attenuatedguthumaninnate immunitymucosal immunitySalmonellatyphoid vaccine

Identifiers

PMID30443257
PMCPMC6221971
OpenAlexW2899348400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.